新闻BioDelivery Sciences International launched ELYXYB TM (celecoxib oral solution on Feb 24th '22.BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYB TM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults.
新闻BioDelivery Sciences International hired John Golubieski as Chief Financial Officer on Oct 21st '21.BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021.
新闻BioDelivery Sciences International promotes Terry Coelho to Executive Vice President and Chief Financial Officer.BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and Chief Financial Officer.
